Objectives: To study the predictors of complementary and alternative medicine (CAM) use in patients with early inflammatory arthritis (EIA), and its impact on delay to initiation of disease-modifying anti-rheumatic drugs (DMARD).
times, which may partly be attributed to early diagnosis and more aggressive treatment targeting remission. 2, 3 It is widely accepted that there is a window of opportunity for treatment in early RA; patients treated early with disease-modifying anti-rheumatic drugs (DMARDs) have a higher chance of attaining remission (including drugfree remission), and accrue less joint damage, leading to less risk of future disability and work loss and increased quality of life. [4] [5] [6] There are various barriers to early initiation of disease-modifying agents, which include delays by the patients themselves, delays in referral by the primary care providers and delays in specialist review due to long waiting times. 7 Several initiatives worldwide focus on public awareness, general practitioner (GP) education and streamlining of the referral process to decrease these delays, thus providing early DMARD therapy to patients with early RA. 8 Most of these initiatives have been described in Western populations.
There are likely to be different social and cultural factors in Asian populations. The use of complementary and alternative medicine (CAM) is common in many Asian societies, especially among patients with chronic diseases, although the limited evidence available does not support its efficacy or effectiveness in RA. 9, 10 Several studies have examined the prevalence and predictors of CAM use; however, its impact has not been previously studied. [11] [12] [13] [14] Owing to the high prevalence of CAM use previously reported in Singapore, 14 and from our clinical observation of many patients trying CAM prior to consulting their primary care physician (PCP), we hypothesized that the use of CAM may impact on early rheumatologist assessment and initiation of DMARD therapy.
The objective of this study was to describe CAM use in our multi-ethnic, Asian patients with early inflammatory arthritis (EIA) (including RA, psoriatic arthritis and undifferentiated arthritis), examine predictors of CAM use, and to determine the association of CAM use with time from symptom onset to DMARD initiation.
MATERIALS AND METHODS
The Singapore Early Arthritis Cohort (SEAC) was set up in September 2013 at two hospitals, the National University Hospital and the Ng Teng Fong General Hospital (NTFGH) (previously Alexandra Hospital, Juronghealth). These are the only two hospitals serving the western area of Singapore and receive patients referred from the four polyclinics (government funded primary care clinics) serving western Singapore. Eighty percent of patients with chronic disease who reside in this geographical area are seen at these polyclinics and anyone requiring specialist care is usually referred to either hospital. 15 All patients with EIA seen by a rheumatologist at either hospital were invited to participate in the SEAC. EIA was defined as inflammation of two or more joints, not caused by trauma, which persisted for more than 4 weeks and was confirmed by rheumatologist assessment. 16 Patients were included if they had selfreported symptom onset after 1 September, 2012. Patients with a known or subsequent diagnosis of connective tissue disease (including systemic lupus erythematosus, primary Sj€ ogren's syndrome, systemic sclerosis etc.), gout, axial spondyloarthritis or primary osteoarthritis were excluded.
Ethics approval was obtained from the National Healthcare Group Domain Specific Review Board and all participants gave informed consent.
Participants were recruited at their routine clinic visit -either at the first rheumatologist review or at the soonest possible visit thereafter. The SEAC is a prospective study with patients followed at 3, 6 and 12 months and then annually for 3 years, with study visits coinciding with the routine rheumatology clinic visit. All patients were interviewed and examined by a research nurse to confirm the diagnosis of EIA and ascertain fulfillment of the American College of Rheumatology (ACR) 1987 criteria or the European League Against Rheumatism (EULAR)/ACR 2010 criteria for RA. 17, 18 All participants completed a nurse-administered questionnaire regarding demographic, health and lifestyle factors, such as occupation, education, current and lifetime smoking, alcohol use and use of CAM. CAM use was defined as the ingestion of tablets, herbs, powder or drinks purported to have medicinal properties, either prescribed by a traditional medicine practitioner, or purchased over the counter. Additionally, acupuncture, therapeutic massages (including acupressure), suction cup therapy when performed for the purpose of therapeutic effect for arthritis, were included. Exercise (including yoga and Tai chi), the use of physiotherapy or occupational therapy and splints were not considered CAM. Details of physician-confirmed medical conditions including cancer, depression, cardiovascular disease (CVD), diabetes mellitus (DM) (type 1/2 not specified), hypertension, chronic lung disease, chronic liver disease, chronic kidney disease, peptic ulcer disease, osteoporosis and previous serious infections, were also ascertained by both self-reporting and review of electronic medical records (EMR). Clinical details such as laboratory test results, imaging and prescriptions were abstracted from the EMR. All participants underwent a clinical examination, including measurement of weight, height, blood pressure, and tender and swollen joint counts. All data were collected on paper forms and later transcribed to a secure online database 'Research Database Capture' or REDCap â . 19 
Statistical analysis
Analyses were conducted in Stata v10 (StataCorp, College Station, TX, USA).
The proportion of current or former CAM users was described, with demographic (age, gender, race), clinical (disease activity, functional status) and sociocultural (education level, language, smoking status) characteristics described as median, interquartile range (IQR) or proportions.
Predictors of CAM use
Multivariate logistic regression was used to determine demographic and clinical predictors of CAM use. Age in tertiles, gender, race (Chinese vs. non-Chinese), language (non-English speaking vs. English speaking), level of education (none or primary vs. secondary or vocational vs. diploma or degree), smoking status (ever vs. never smokers), disease activity (measured using the Disease Activity Score in 28 joints ([DAS28]: low, < 3.2 vs. moderate, ≥ 3.2 to < 5.1 vs. high, ≥ 5.1) 20, 21 and functional disability (measured using the eight-item modified Health Assessment Questionnaire, mHAQ) 22 were all modeled as categorical variables. Variables found to have a trend to significance (P ≤ 0.2) on univariate analysis were included in the multivariate model. Results are presented as odds ratios (OR) and 95% confidence intervals (CI).
Association of CAM use with time to DMARD therapy CAM use as a determinate of time from symptom onset to initiation of DMARD was examined by survival analysis by Kaplan-Meier plots. Additionally, predictors of time to DMARD initiation were examined by Cox proportional hazards regression. First, the association of CAM with time to DMARD prescription was tested by univariate cox regression. Age, gender, race, language, level of education, smoking status, seropositivity (rheumatoid factor [RF] or anti-citrullinated peptide antibody [ACPA] positive), DAS28, mHAQ (all categorized as above) were each tested separately by univariate Cox regression. The point estimates for moderate and high disease activity were similar, and were thus combined into one group. Age, gender as well as variables with a trend to significance (P ≤ 0.2) were entered into the multivariate model. Results are presented as hazard ratios (HR) and 95% CIs. Missing data (< 2%) were ignored.
RESULTS

Disease characteristics and demographics
Only baseline data were used for the purpose of this analysis. A total of 180 patients were included (of 186 recruited) in the SEAC as of September 2015. Six patients were excluded either because of alternate diagnosis (two), onset of symptoms prior to September 2012 (three) and refusal of consent (one).
Patients were recruited into the SEAC as soon as possible after diagnosis; thus the median (IQR) disease duration from the time of diagnosis to recruitment was 3 (0-16.9) weeks. The median (IQR) age was 51.1 (40.9-59.8) years and 70.6% were women. One hundred and fifty-one (83.9%) had physician-diagnosed rheumatoid arthritis, 23 (12.8%) had psoriatic arthritis and six (3.3%) had undifferentiated inflammatory arthritis. The majority of patients were Chinese, about half were seropositive. Of the 151 patients with baseline X-rays, 25.2% had erosions. Patients had moderately active disease, with median (IQR) DAS28 of 4.3 (2.8-5.7), median (IQR) tender joint (28) Table 1 .
CAM use
Seventy-four (41.3%) of 179 patients (one missing) admitted to use of CAM. CAM use was especially prevalent in Chinese patients (58.1%). Oral tablets or powder (55.1% of CAM users) and acupuncture (46.9%) were the most common types of CAM. Most CAM in our cohort consisted of traditional Chinese medicine. Users of CAM were more likely to be older, of Chinese race, non-English speaking, smokers and have high disease activity. In a multivariate model, Chinese race, being non-English speaking, smoking and high DAS28 were independent predictors of CAM use ( Table 2) .
The median time from symptom onset to first rheumatologist review in the SEAC was 16.6 (IQR 9.2-26.6) weeks. Most patients received a diagnosis at the first rheumatologist visit, and had DMARDs initiated the same day or soon after. Thus, median time from symptom onset to initiation of first DMARD was 17. Figure 1 shows the Kaplan-Meier survival curve for time to DMARD prescription. In univariate analysis, only CAM use was significantly associated with time to first DMARD prescription, while DAS28 and mHAQ showed a trend to significance. Age, gender, education level, race and seropositivity were not associated with time to first DMARD. Age, gender, CAM use, mHAQ and DAS28 (in two groups, low vs. moderate or high disease activity) were included in the multivariate model. In the final multivariate model adjusted for age and gender, CAM use and higher DAS28 were associated with a longer time to DMARD initiation (HR 0.69, 95% CI 0.50-0.95 and 0.63, 95% CI 0.43-0.91, respectively, for 'risk' of starting DMARD) while higher mHAQ was associated with a shorter delay (HR 1.59, 95% CI 1.08-2.34) ( Table 3) .
DISCUSSION
CAM use was highly prevalent in our cohort and was an independent factor delaying the start of DMARD therapy in patients with EIA, after adjusting for potential confounders such as age, gender, race, education level, seropositivity, disease activity and functional status. This is the first study, to our knowledge, to study the impact of CAM on an important quality indicator in EIA. Additionally, the data are derived from the first true prospective, inception cohort of Asian patients with EIA. While early arthritis cohorts were established in Europe and the USA more than a decade ago, there are no equivalent cohorts in Asia. 16, [23] [24] [25] [26] Previous Asian cohorts include the Japanese IORRA (Institute of Rheumatology, Rheumatoid Arthritis) and the Korean KORONA (Korean Observational Study Network for Arthritis) both of which include patients with established RA and the Malaysian MyEIRA (Malaysian Epidemiological Investigation of Rheumatoid Arthritis) which was a case control study of early RA, with median disease duration of 1 year. [27] [28] [29] Our study is thus uniquely placed to provide important information on the genetic and sociocultural influences on the natural history of RA in the Asian population.
CAM use is common in patients with chronic disease, and the frequency of its use in RA has been well described, especially in traditional Asian societies. [11] [12] [13] 30, 31 Singapore is a developed country with good healthcare facilities and outcomes; yet traditional beliefs and therapies remain deeply ingrained, with widespread practice of and belief in CAM, especially in patients with chronic musculoskeletal disease or chronic pain. CAM users were more likely to be older, Chinese and non-English speaking. Taken together, these likely represent a group of patients with more traditional health beliefs. Previous studies from Korea and Japan suggest that female gender, presence of depression and dissatisfaction with DMARD therapy may predict CAM use. 11, 13 In addition, we found smoking and higher disease activity to be associated with CAM use. Smoking is known to be associated with seropositive RA and together with higher disease activity, is likely a marker for more severe disease. [32] [33] [34] It is precisely these patients who would benefit from early DMARD initiation to prevent radiographic progression and disability, underlining the public health importance of CAM use in this population.
A higher DAS28 was independently associated with delayed time to DMARD initiation, even after adjusting for CAM use. Conversely, a higher mHAQ predicted less delay in our cohort. Understandably, those with impaired physical function presented early; however, late presentation with higher DAS28 is difficult to explain. The delay from symptom onset to initiation of first DMARD includes time from symptom onset to first PCP visit (patient delay) plus delay from first PCP visit to specialist referral (PCP delay) plus time from PCP referral to rheumatologist review (referral delay). 7 Referral delay at our center is minimal, with more than 70% of early arthritis patients triaged to early review within 2 weeks. 35 Moreover, time from rheumatologist review to initiation of DMARD therapy was negligible, with most patients initiating therapy on the same day. Thus, the main delay to DMARD initiation was from patient delay and PCP delay. It is possible that patients with higher DAS28 were more likely to be prescribed non-steroidal anti-inflammatory drugs or corticosteroids by their PCP, or have blood tests ordered by their PCP prior to referral, thus increasing PCP delay. Overall, patients in our cohort initiated DMARD at a median of 17.4 (10.6-27.1) weeks from symptom onset. While this is more than the recommended 12 weeks, it compares favorably with other early arthritis cohorts in developed countries and is much shorter than that reported in developing countries. 3, 36, 37 Previous studies have suggested lower socioeconomic status (SES), lower number of swollen joints, seropositivity and presence of other comorbid conditions such as fibromyalgia and osteoarthritis to be associated with delayed presentation. [38] [39] [40] [41] In our study, education level and being non-English speaking were used as surrogates for SES; however, these were not associated with increased delay to DMARD prescription. It is possible though, that patients of higher SES consulted a private rheumatologist rather than our public sector hospitals, and may have thus been excluded from our study.
Our study has several strengths. It is a prospective, inception cohort, and all patients were interviewed and examined by a trained nurse, supplemented by detailed medical record review. Although our patients were recruited from specialist rheumatology clinics, selection bias is less likely as most patients would have been referred to one of our two centers, and almost all eligible patients consented to participate. We deliberately included patients with EIA as it has been previously shown that these patients continue to cumulatively satisfy criteria for RA up to 5 years. There were several limitations to our study. Our patient numbers were small. While all efforts were made to approach and include all patients with EIA, some patients were inadvertently missed; however, it is unlikely that these patients would differ from the included patients. We were unable to look at the effect of SES on time to DMARD initiation as direct SES data were unavailable. Moreover, occupation could not be used as a surrogate as the majority of women in our cohort were homemakers; hence education level was used instead, and has been previously validated as a marker of SES. 42 In this study, we have described crosssectional data with time to initiation of DMARD as our primary outcome. In future, it would be useful to study if continuing CAM use impacts on disease outcomes such as remission or functional disability. However, we know from previous literature that early DMARD initiation is a predictor of these outcomes. [4] [5] [6] In summary, we have shown that CAM is highly prevalent and its use is common in older, non-English speaking Chinese smokers with high disease activity and is associated with a delay in presentation and initiation of DMARD therapy. Healthcare professionals should be aware of these unique challenges in treating patients with EIA in Asia. Patient and public education campaigns to increase awareness of the importance of early treatment in patients with EIA are urgently needed. However, changing cultural norms and healthcare beliefs is likely to be challenging.
